MedTrace Logo

Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes

NCT01007110 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2014-06-09

Study results available
· View outcomes & findings →

Summary

DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart rate and blood pressure and increasing heart variability. Little is known about how fatty acids impact cardiac control in infants, children or the fetus. Our hypothesis is that maternal DHA supplementation (600 mg/day) will lower fetal HR and increase fetal HRV.

Conditions

  • Pregnancy

Interventions

DIETARY_SUPPLEMENT

DHA

Docosahexaenoic Acid (DHA) from algal oil

OTHER

Placebo

Placebo capsule

Sponsors & Collaborators

  • University of Kansas

    lead OTHER

Principal Investigators

  • Kathleen Gustafson, PhD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-05-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01007110 on ClinicalTrials.gov